Guggenheim Maintains Neutral on Amgen, Lowers Price Target to $378
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.
Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and lowers the price target from $388 to $378.